|[October 07, 2013]
Tony Coles, Former Onyx Pharmaceuticals Chairman and CEO, to give keynote at BIO-Europe® 2013 in Vienna November 4-6
ZURICH & VIENNA --(Business Wire)--
Tony Coles, MD, Former Chairman and CEO of Onyx Pharmaceuticals,
Inc., will give the opening keynote at the 19th annual
BIO-Europe® international partnering conference in Vienna, Austria,
November 4-6, 2013.
Coles' presentation, "The Onyx Story: Creating a Leading Oncology
Company," is expected to be a big draw at the event just as Amgen and
Onyx Pharmaceuticals close their buyout deal valued at USD 10.4 billion.
The buyout is the culmination of an impressive run for Onyx with the
success of their multiple myeloma drug Kyprolis earlier this year, and
the steady revenue influx from Stivarga, a treatment for colorectal
cancer and a rare form of gastric cancer. Coles' leadership in R&D and
commercialization strategies at Onyx is considered to be a critical
factor in the buyout. Insiders hope the keynote will reveal some of the
backstory behind Coles' genius from his 20-year plus career in the
industry, and details about the Amgen acquisition.
Organized by EBD Group in collaboration with the Biotechnology Industry
Organization (BIO) and local host Life Science Austria Vienna
(LISAvienna), the event is Europe's largest partnering conference
serving the global biotechnology industry.
In addition to the keynote and informative program panels, BIO-Europe is
recognized for having high-caliber attendance of senior executives from
innovative biotech companies and big pharma who come specifically to
participate in one-to-one partnering meetings. Company presentations are
also a magnet at BIO-Europe and provide direct access to innovation in
the sector. A new track this year is the Academic Innovators™ Showcase
in response to pharma's interest in increased access to academia. The
showcase is designed to shine a spotlight on extraordinary scientific
advances with strong translational potential, and features presentations
from nonprofit universities, institutes and hospitals who are actively
conducting preclinical research within a noncommercial setting.
Registration for BIO-Europe is open until November 1 on the BIO-Europe
event website, and thereafter on site.
LISAvienna - Life Science Austria Vienna is the life science cluster
organization of the City of Vienna, serving all stakeholders in the
areas of biotechnology/pharmaceuticals and medical technology.
As a joint initiative of the Republic of Austria and the City of Vienna,
LISAvienna helps to ensure that the economic potential of life sciences
is put to good use and turned into marketable products, improved
processes and new services. The main focus of its activities is on
custom-tailored advice and assistance for innovative enterprises.
LISAvienna is supported by Austria Wirtschaftsservice GmbH (aws) and the
ZIT - The Technology Agency of the City of Vienna.
About BIO-Europe 2013
The 19th annual BIO-Europe® event will be the largest biotechnology
partnering conference held in Europe.Over 3,000 global decision makers
from biotechnology, pharma and finance, representing upwards of 1,700
companies from over 50 countries, annually attend BIO-Europe to identify
new business opportunities and develop strategic relationships.
BIO-Europe features the industry's most advanced web-based partnering
system enabling delegates from all parts of the biotechnology value
chain to quickly identify, engage and enter into strategic relationships
that drive their business successfully forward. BIO-Europe will take
place November 4-6, 2013 in Vienna, Austria.
Follow BIO-Europe 2013 on Twitter (News - Alert): twitter.com/ebdgroup
Notes to Editors:
Entry to BIO-Europe 2013 is free to members of the press, including full
access to the partnering system, sessions, press conferences, workshops,
and pre-arranged partnering meetings. Visit the BIO-Europe conference
website at http://www.ebdgroup.com/bioeurope/registration/press_reg.php
for registration details.
About EBD Group
EBD Group is the leading partnering firm for the global life science
industry. Since 1993, biotech, pharma and medical device companies have
leveraged EBD Group's partnering conferences, technology and services to
identify business opportunities and develop strategic relationships
essential to their success.
EBD Group's conferences are run with the support of leading corporations
and international trade associations and include:
BIO-Europe Spring®, Europe's largest life science partnering
conferences, supported by the Biotechnology Industry Organization (BIO)
America™, the fastest growing partnering event in North America
Showcase™, a unique forum in San Francisco for presenting to
investors and business development executives, co-produced with
Demy-Colton Life Science Advisors
Europe, the investor conference co-organized with BioCentury
Publications and BIO
Partnering Forum, the first dedicated biotech/pharma partnering
conference in China, co-produced with ChinaBio® LLC
EBD Group's partnering event for the innovative medical technology
for Global Impact®, an inspirational partnering conference
providing an innovative forum to partner, identify and generate social
and philanthropic investment and funding opportunities
EBD Group's sophisticated web-based partnering service, partneringONE®,
is used as the partnering engine at numerous third-party events around
the world, and partnering360® is the open
online community of life science dealmakers that enhances partnering
experiences throughout the year.
EBD Group is an Informa (News - Alert) company. Informa is the largest publicly-owned
organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131007005132/en/
[ Back To Technology News's Homepage ]